This application supports the participation of the University of Chicago in Cancer and Leukemia Group B (CALGB) trials, including scientific and regulatory activities. The CALGB develops and performs clinical trials, primarily large scale clinical trials, to advance the treatment of cancer patients. The University of Chicago is a leading member of CALGB, supplying scientific and administrative leadership including the Group Chair (Dr Schilsky), Committee Chairs (Drs Ratain, Vokes, and Larson), and Study Chairs. Preliminary studies performed at the University of Chicago are taken to CALGB for large scale testing. Laboratories at the University of Chicago perform correlative studies that support CALGB trials. University of Chicago senior faculty mentor junior faculty and fellows in cooperative group participation, with large meeting attendance and eight CALGB Foundation grants awarded to University of Chicago fellows and junior faculty during the past granting period. In addition, The University of Chicago and its eight affiliate institutions are consistently among the top five accruers to CALGB studies with broad participation across all tumor types and substantial minority accrual.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA041287-27
Application #
8249784
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1986-09-30
Project End
2015-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
27
Fiscal Year
2012
Total Cost
$258,606
Indirect Cost
$92,833
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Coutre, Steven E; Othus, Megan; Powell, Bayard et al. (2014) Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol 165:497-503
Wetzler, Meir; Watson, Dorothy; Stock, Wendy et al. (2014) Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica 99:111-5
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7
Wang, Xiaofeng; Owzar, Kouros; Gupta, Pankaj et al. (2014) Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol 78:1005-13
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32

Showing the most recent 10 out of 177 publications